Multicenter evaluation of pramiracetam for the treatment of memory impairment of probable vascular origin

P. Scarpazza, E. E. Guffanti, E. Marchi, F. Corsonello, A. Vozza, I. Spezie

Research output: Contribution to journalArticle

Abstract

This multicenter, open, noncomparative study involved 104 elderly patients with cognitive impairment of probable vascular origin. On the basis of Mini- Mental State Examination score, patients were further characterized as having mild or moderate memory impairment. Pramiracetam was administered orally twice a day at 600 mg for 3 months. Patients were evaluated before treatment and after 30, 60, and 90 days by means of the Mini-Mental State, Information- Memory-Concentration, Figures Repetition, and Rey's 15 Words tests. Pramiracetam proved to be safe and clinically effective in improving mental deterioration, with an order of magnitude closely related to the severity of the memory disorder.

LanguageEnglish
Pages217-225
Number of pages9
JournalAdvances in Therapy
Volume10
Issue number5
StatePublished - 1993

Fingerprint

Blood Vessels
Memory Disorders
Therapeutics
pramiracetam
Cognitive Dysfunction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Scarpazza, P., Guffanti, E. E., Marchi, E., Corsonello, F., Vozza, A., & Spezie, I. (1993). Multicenter evaluation of pramiracetam for the treatment of memory impairment of probable vascular origin. Advances in Therapy, 10(5), 217-225.

Multicenter evaluation of pramiracetam for the treatment of memory impairment of probable vascular origin. / Scarpazza, P.; Guffanti, E. E.; Marchi, E.; Corsonello, F.; Vozza, A.; Spezie, I.

In: Advances in Therapy, Vol. 10, No. 5, 1993, p. 217-225.

Research output: Contribution to journalArticle

Scarpazza, P, Guffanti, EE, Marchi, E, Corsonello, F, Vozza, A & Spezie, I 1993, 'Multicenter evaluation of pramiracetam for the treatment of memory impairment of probable vascular origin' Advances in Therapy, vol. 10, no. 5, pp. 217-225.
Scarpazza P, Guffanti EE, Marchi E, Corsonello F, Vozza A, Spezie I. Multicenter evaluation of pramiracetam for the treatment of memory impairment of probable vascular origin. Advances in Therapy. 1993;10(5):217-225.
Scarpazza, P. ; Guffanti, E. E. ; Marchi, E. ; Corsonello, F. ; Vozza, A. ; Spezie, I./ Multicenter evaluation of pramiracetam for the treatment of memory impairment of probable vascular origin. In: Advances in Therapy. 1993 ; Vol. 10, No. 5. pp. 217-225
@article{a559d1898fc54d4f9f25738e05d95d9b,
title = "Multicenter evaluation of pramiracetam for the treatment of memory impairment of probable vascular origin",
abstract = "This multicenter, open, noncomparative study involved 104 elderly patients with cognitive impairment of probable vascular origin. On the basis of Mini- Mental State Examination score, patients were further characterized as having mild or moderate memory impairment. Pramiracetam was administered orally twice a day at 600 mg for 3 months. Patients were evaluated before treatment and after 30, 60, and 90 days by means of the Mini-Mental State, Information- Memory-Concentration, Figures Repetition, and Rey's 15 Words tests. Pramiracetam proved to be safe and clinically effective in improving mental deterioration, with an order of magnitude closely related to the severity of the memory disorder.",
author = "P. Scarpazza and Guffanti, {E. E.} and E. Marchi and F. Corsonello and A. Vozza and I. Spezie",
year = "1993",
language = "English",
volume = "10",
pages = "217--225",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",
number = "5",

}

TY - JOUR

T1 - Multicenter evaluation of pramiracetam for the treatment of memory impairment of probable vascular origin

AU - Scarpazza,P.

AU - Guffanti,E. E.

AU - Marchi,E.

AU - Corsonello,F.

AU - Vozza,A.

AU - Spezie,I.

PY - 1993

Y1 - 1993

N2 - This multicenter, open, noncomparative study involved 104 elderly patients with cognitive impairment of probable vascular origin. On the basis of Mini- Mental State Examination score, patients were further characterized as having mild or moderate memory impairment. Pramiracetam was administered orally twice a day at 600 mg for 3 months. Patients were evaluated before treatment and after 30, 60, and 90 days by means of the Mini-Mental State, Information- Memory-Concentration, Figures Repetition, and Rey's 15 Words tests. Pramiracetam proved to be safe and clinically effective in improving mental deterioration, with an order of magnitude closely related to the severity of the memory disorder.

AB - This multicenter, open, noncomparative study involved 104 elderly patients with cognitive impairment of probable vascular origin. On the basis of Mini- Mental State Examination score, patients were further characterized as having mild or moderate memory impairment. Pramiracetam was administered orally twice a day at 600 mg for 3 months. Patients were evaluated before treatment and after 30, 60, and 90 days by means of the Mini-Mental State, Information- Memory-Concentration, Figures Repetition, and Rey's 15 Words tests. Pramiracetam proved to be safe and clinically effective in improving mental deterioration, with an order of magnitude closely related to the severity of the memory disorder.

UR - http://www.scopus.com/inward/record.url?scp=0027458140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027458140&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 217

EP - 225

JO - Advances in Therapy

T2 - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 5

ER -